Skip to main content
< Back to news
From left to right, Rosa Maria Moreno, Joan Feixas and Laura Grau. Photo / Barcelona Science Park.
 03.02.2025

Enantia joins Inveready to lead the formation of a group specialising in R&D services

Enantia, a renowned contract research organisation (CRO) with more than 20 years’ experience in chemistry services and located in the Parc Científic de Barcelona (PCB), has been acquired by INVACO, a company controlled by the venture capital fund Inveready Biotech IV, specialised in life sciences and healthcare. With this operation, it initiates an ambitious process of growth and build-up of small CROs specialised in providing R&D services in the field of life sciences and healthcare.

The collaboration between Inveready and Enantia’s management team – which will continue to be a shareholder – will drive the company’s expansion into new markets. In addition, it will enable the execution of a CRO acquisition strategy to consolidate a specialised group offering comprehensive R&D services to its customers.

Enantia provides research and development services in medicinal chemistry, chemical and process R&D and solid state R&D. The company operates from its facilities in Esplugues de Llobregat and the PCB, where it has laboratories for medicinal chemistry, process development and chemical analysis projects. The Esplugues de Llobregat facilities also have offices and laboratories dedicated to the study of the solid state of active pharmaceutical ingredients. With a team of highly trained professionals, Enantia ensures the highest-quality service.

Joan Feixas, CEO of Enantia, said: “We appreciate the trust that Inveready has placed in Enantia and its management team to lead the creation of a group aimed at offering R&D services with a broader and more value-added approach, not only in the field of life sciences, but also in other sectors. It is a great growth opportunity that comes at the perfect time and at the right juncture. We are excited to be part of this project.”

Sara Secall, partner in Inveready, commented: “We believe that the preclinical CRO sector is very atomised in Spain. We created INVACO with the objective of acquiring contract research organisation, or CRO-type companies in life sciences. Enantia is the first company we integrated into the group, and we intend to acquire other small CRO companies, specialised in R&D services for third parties in preclinical drug development areas such as formulations, analytical and bioanalytical methods, toxicology and pilot productions. We are breathing new life into the company’s shareholding by providing an exit for historical shareholders and incentive for the management team by incorporating them as INVACO shareholders.”